Development of Fluoroquinolones as First-line Drugs for Tuberculosis - At Long Last!

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 11, 2003, Pages 1266-1268

  O'Brien, Richard J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAPENTINE;

ANTIBIOTIC RESISTANCE; DRUG POTENCY; DRUG SENSITIVITY; EDITORIAL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS;

FLUOROQUINOLONES; HUMANS; TUBERCULOSIS, PULMONARY;

EID: 0344825065     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2309011     Document Type: Editorial

References (15)

1. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-356.
2. American Thoracic Society/Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
3. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
4. Tuberculosis Research Centre. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002;49:27-38.
5. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147:1062-1063.
6. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, et al. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
7. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:1022-1025.
8. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657.
9. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J. Antimicrob Chemother 2000;46: 669-683.
10. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42: 2066-2069.
11. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.
12. rd Annual ICAAC, Chicago, Sept. 13-17, 2003.
13. Global Alliance for TB Drug Development. Scientific blueprint for TB drug development. Tuberculosis (Edinb) 2001;81:1-52.
14. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-1345.
15. O'Brien RJ. Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development? Am J Respir Crit Care Med 2002;166:3-4.